Home Cart Sign in  
Chemical Structure| 1429882-07-4 Chemical Structure| 1429882-07-4

Structure of MRX-2843
CAS No.: 1429882-07-4

Chemical Structure| 1429882-07-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MRX-2843 (UNC2371) is an orally active, ATP-competitive MERTK and FLT3 tyrosine kinase inhibitor (TKI) with IC50 values of 1.3 nM and 0.64 nM, respectively.

Synonyms: UNC2371

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MRX-2843

CAS No. :1429882-07-4
Formula : C29H40N6O
M.W : 488.67
SMILES Code : O[C@H]1CC[C@H](N2C=C(C3=CC=C(CN4CCN(C)CC4)C=C3)C5=CN=C(NCCC6CC6)N=C52)CC1
Synonyms :
UNC2371
MDL No. :MFCD28502224

Safety of MRX-2843

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of MRX-2843

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03510104 Advanced Cancer|Metastatic Can... More >>cer|Neoplasms|Neoplasm Metastasis|Neoplastic Processes|Pathologic Processes Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-04-25 Emory University, Atlanta, Geo... More >>rgia, 30322, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27514, United States Less <<
NCT04872478 Acute Myeloid Leukemia|Acute L... More >>ymphoblastic Leukemia|Mixed Phenotype Acute Leukemia Less << PHASE1 RECRUITING 2026-03-31 Emory University - WINSHIP Can... More >>cer Center, Atlanta, Georgia, 30322, United States|Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.05mL

0.41mL

0.20mL

10.23mL

2.05mL

1.02mL

20.46mL

4.09mL

2.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories